Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker

Cancer Research

Volumn 50, Issue 20, 1990, Pages 6600-6607

  Greenfield, Robert S ^a   Kaneko, Takushi ^a   Daues, Ann ^a   Edson, Mary A ^a   Fitzgerald, Kathleen A ^a   Olech, Lee J ^a,b   Grattan, James A ^a   Spitalny, George L ^a   Braslawsky, Gary R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BIO RAD LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY LABELING; ARTICLE; CYTOCHEMISTRY; HUMAN; HUMAN CELL; METHODOLOGY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CELL SURVIVAL; DITHIOTHREITOL; DOXORUBICIN; DRUG STABILITY; HUMAN; HYDRAZONES; IMMUNOTOXINS; TUMOR CELLS, CULTURED;

EID: 0025185802     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mathe, G., Maral, R., and DeJager, R. Anthracyclines. Current Status and Future Developments. New York: Masson Publishing USA, 1982.
2. Casazza, A. M., Isetta, A. M., Giuliani, F., and DiMarco, A. Immunode-pressive activity of daunomycin and Adriamycin. In: M. Staquet, H. Tagnon, Y. Kenis, G. Bonadorna, S. K. Carter, G. Sokal, G. Trouet, M. Ghione, C. Praga, L. Lenaz, and O. S. Karin (eds.), Adriamycin Review, pp. 123–131. Medikon, Belgium: European Press, 1975.
3. Ghose, T. I., Blair, A. H., and Kulkarni, P. N. Preparation of antibody-linked cytotoxic agents. Methods Enzymol., 93: 280–333, 1983.
4. Anion, R., and Sela, M. In vitro and In vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol. Rev., 62: 5–27, 1982.
5. Upeslacis, J., and Hinman, L. Chemical modification of antibodies for cancer chemotherapy. Annu. Rep. Med. Chem., 23: 151–160, 1988.
6. Hurwitz, E., Maron, R., Arnon, R., Wilchek, M., and Sela, M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res., 35: 1175–1181, 1975.
7. Levy, R., Hurwitz, E., Maron, R., Arnon, R., and Sela, M. The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Res., 35: 1182–1186, 1975.
8. Belles-Isles, M., and Page, M. In vitro activity of daunomycin-anti-alphafe-toprotein conjugate on mouse hepatoma cells. Br. J. Cancer, 41: 841–842, 1980.
9. Hurwitz, E., Maron, R., Arnon, R., Wilchek, M., and Sela, M. Daunomycin-immunoglobulin conjugates, uptake and activity in vitro. Eur. J. Cancer, 14: 1213–1220, 1978.
10. Hurwitz, E., Kashi, R., Burowsky, J. D., Arnon, R., and Haimovich, J. Site-directed chemotherapy with drug bound to anti-idiotypic antibody to a lymphoma cell-surface IgM. Int. J. Cancer, 31: 745–748, 1983.
11. Pimm, M. V., Jones, J. A., Price, M. R., Middle, J. G., Embleton, M. J., and Baldwin, R. W. Tumor localization of monoclonal antibody against rat mammary carcinoma and suppression of tumor growth with adriamycin antibody conjugates. Cancer Immunol. Immunother., 12: 125–134, 1982.
12. Yamamoto, K., Acton, E. M., and Henry, P. W. Antitumor activity of some derivatives of daunomycin at the amino and methylketone functions. J. Med. Chem., 15: 872–875, 1972.
13. DiMarco, A. Adriamycin (NSC-123127): mode and mechanism of action. Cancer Chemother. Rep., 6: 91–106, 1975.
14. Dillman, R. O., Shawler, D. L., Johnson, D. E., Meyer, D. L., Koziol, J. A., and Frincke, J. M. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res., 46: 4886–4891, 1986.
15. Yang, H. M., and Reisfeld, R. A. Doxorubicin conjugated to a monoclonal antibody directed against a melanoma-associated proteoglycan suppresses growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 85: 1189–1193, 1988.
16. Dillman, R. O., Johnson, D. E., Shawler, D. L., and Koziol, J. A. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res., 48: 6097–6102, 1988.
17. Gallego, J., Price, M. R., and Baldwin, R. W. Preparation of four dauno-mycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. Int. J. Cancer, 33: 737–744, 1984.
18. Pietersz, G. A., Smyth, M. J., and McKenzie, I. F. C. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res., 48: 926–931, 1988.
19. Bruck, C., Portetelli, D., Glineur, C., and Bollen, H. One-step purification of mouse monoclonal antibodies from ascitic fluid by DEAE-affigel blue chromatography. J. Immunol. Methods, 53: 313–319, 1982.
20. Ellman, G. L. Tissue sulfhydryl groups. Arch. Biochem. Biophys., 82: 70–77, 1959.
21. Colombatti, M., Nabholz, M., Gros, O., and Brown, C. Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures. J. Immunol., 131: 3091–3095, 1983.
22. Ogden, J. R., Leung, K., Kunda, S. A., Telander, M. W., Avner, B. P., Liao, S. K., Thurman, G. B., and Oldham, R. K. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Mol. Biother., 1: 170–174, 1989.
23. Tsukada, Y., Kato, Y., Umemoto, N., Takeda, Y., Hara, T., and Hirai, H. An anti-a-fetoprotein antibody-daunomycin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier. J. Natl. Cancer Inst., 73: 721–729, 1984.
24. Pastan, I., and Willingham, M. C. (eds.). Pathway of endocytosis. In: Endocytosis, pp. 1–44. New York: Plenum Publishing Corp., 1985.
25. Tritton, T. R., and Yee, G. The anticancer agent Adriamycin can be actively cytotoxic without entering cells. Science (Washington DC), 217: 248–250, 1982.
26. Braslawsky, G. R., Edson, M. A., Pearce, W., Kaneko, T., and Greenfield, R. S. Antitumor activity of Adriamycin (Hydrazone-linked) immunoconjugates compared with free Adriamycin and specificity of tumor cell killing. Cancer Res., 50: 6600–6607, 1990.